Company intelligence / Profile preview
Intima Bioscience
New York City, New York, USAintimabioscience.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Intima Bioscience is conducting Phase 1/2 clinical trials evaluating the safety and efficacy of autologous tumor-infiltrating lymphocytes genetically engineered via CRISPR to knock out the CISH immune checkpoint. Early-stage results are not yet published, but the company is actively enrolling patients with metastatic gastrointestinal cancers.
- Therapeutic areas
- Oncology
- Modalities
- Tumor-infiltrating lymphocytes (TILs)Genetically engineered cell therapyCRISPR/Cas9 gene editingmRNA (pipeline includes at least one mRNA program)AAV-based gene therapy (in discovery phase)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
MaxCyte – licensing agreement for Flow Electroporation® technology and ExPERT™ platform [5],[8]
Beyond the preview
Go deeper on Intima Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intima Bioscience.